Predictive Value of Osteopontin for Contrast Nephropathy (NCT05547581) | Clinical Trial Compass
UnknownNot Applicable
Predictive Value of Osteopontin for Contrast Nephropathy
155 participantsStarted 2022-12-07
Plain-language summary
Early detection of contrast induced nephropathy by using osteopontin as an early marker for prediction
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
\- patients undergoing coronary with or without intervention between 2022and 2024 were prospectively enrolled at the study.
Patients were referred for angiography for various acute and nonacute indications, including acute coronary syndromes, heart failure, abnormal stress tests, stable chest pain, claudication, and routine preoperative evaluation.
Patient with CKD stage 1 or 2 only
Exclusion Criteria:
* Pt has history of contrast induced nephropathy before. Patient known to have Chronic kidney disease stage 3A upto 5D Pt has contraindication for coronary angiograghy.
What they're measuring
1
early detection of patients at risk of (CA-AKI) before angiographic procedures